A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal CAnal
This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
NCT02314169 — Anal Canal Squamous Cell Carcinoma
Status: Active, not recruiting
http://inclinicaltrials.com/anal-canal-squamous-cell-carcinoma/NCT02314169/
The purpose of the study is to identify biomarkers and potentially actionable mutations/ activated molecular pathways and evaluate the impact of molecular profiling information on patients with cancer. The hypothesis of the study are: - Analysis of tumour samples will allow us to identify novel and/or actionable molecular changes that may drive therapeutic strategies for the management of cancers. - Molecular profiling will improve the outcome of novel targeted-agent treatment in clinical trials - Molecular profiling of paired samples (primary/recurrent and primary/metastatic) will provide new insights into mechanisms underlying drug resistance and metastasis in cancers.
NCT02078544 — Cancer
Status: Recruiting
http://inclinicaltrials.com/cancer/NCT02078544/
Breast Cancer Molecular Analysis Prior to Investigational Therapy
This is a molecular testing study for patients with metastatic breast cancer. The purpose of this study is to find defects in the DNA of the cancer that could potentially be treated with US Food and Drug Administration (FDA)approved or investigational drugs. For example, if your cancer has a mutation in the Epidermal Growth Factor Receptor (EGFR) gene (a mutation is a change int he DNA sequence of a gene) that makes this receptor "superactive" a drug that inhibits this receptor may also inhibit the growth of the cancer. If this genetic defect is not present in the cancer the same drug may not work. This EGFR gene mutation based patient selection for treatment has worked in lung cancer and we are testing its value in breast cancer. What drugs may be available against particular genetic abnormalities in the context of this clinical study will change over time.
NCT01855503 — Metastatic Breast Cancer
Status: Completed
http://inclinicaltrials.com/metastatic-breast-cancer/NCT01855503/
Exercise in Breast Cancer Survivors: Analysis of Angiogenic Profile
The investigators hypothesize that exercise in postmenopausal breast cancer survivors will result in an increase in the plasma concentrations of angiostatic factors and a decrease in the plasma concentrations of angiogenic factors. Exercise is expected to result in a circulating angiostatic phenotype that inhibits adipose tissue mass, growth of breast cancer tumor, growth of microscopic residual disease after breast cancer resection, decreases rates of local-regional recurrence, decreases rates of distant recurrence, and increases survival.
NCT01582685 — Breast Cancer
Status: Withdrawn
http://inclinicaltrials.com/breast-cancer/NCT01582685/
Cancer Genome Analysis
Next generation sequencing (including targeted gene seqeuncing, exome and transcriptome sequencing) will be performed from fresh frozen tumor samples to understand the genetic alteration of tumors and to aid in optimal selection of further therapeutic agents.
NCT01458704 — Malignant Tumor
Status: Recruiting
http://inclinicaltrials.com/malignant-tumor/NCT01458704/
A Phase II Clinical Study Using Nimotuzumab in Combination With External Beam Radiation Therapy in the Treatment of Patients With Carcinomas of the Anal CAnal
The objective of this study is to demonstrate the feasibility of using Nimotuzumab and radiation in the treatment of squamous cell carcinomas of the anal canal in order to achieve a 65% local control rate with a better toxicity profile than the conventional treatment. Patients with high toxicity risks (HIV+ and fragile patients) will be selected for this study.
NCT01382745 — Squamous Cell Carcinoma of Anal Canal
Status: Terminated
http://inclinicaltrials.com/squamous-cell-carcinoma-of-anal-canal/NCT01382745/
Surgery for Endometrial Cancer: Biobehavioral Analysis of Sleep, Stress and Pain
This study proposes to test the hypothesis that zolpidem taken the night before major surgery for endometrial cancer will improve sleep efficiency and reduce post surgery pain, as well as reduce the need for analgesic medication.
NCT00936598 — Pain
Status: Terminated
http://inclinicaltrials.com/pain/NCT00936598/
Genital Drop Technique With Intensity-Modulated Radiation Therapy (IMRT) in Male Anal and Distal Rectal Cancer Patients: A Dosimetric Comparison
The study compares two patient setups (Standard Prone vs. Genital Drop Technique) with identical radiation treatment technique and parameters. After the two setups have been planned, the treating faculty reviews the setups and will choose the setup he feels that will give the patient improved dosimetry to the local regions and hopefully reduce toxicity and improve treatment tolerability.
NCT00693173 — Anal Cancer
Status: Completed
http://inclinicaltrials.com/anal-cancer/NCT00693173/
Role of Methadone As Co-Opioid Analgesic in Cancer Patients
Objectives: Primary Objective: To determine whether the addition of low dose methadone to morphine(in the methadone group) has a lower dose escalation index as compared to the morphine alone(in the morphine group) at Day 15 (+/- 3 days) Secondary Objectives: To determine whether individuals on the methadone arm have lower pain intensity than the morphine alone arm as demonstrated by a decrease in two points from baseline (+/- 3 days) in their ESAS score at Day 15 (+/- 3 days). To determine whether the methadone group of experiences fewer opioid induced neurotoxic side effects (including sedation, myoclonus, hallucinations, hyperalgesia and confusion) as compared to the morphine alone group at Day 15 (+/- 3 days).
NCT00558870 — Pain
Status: Terminated
http://inclinicaltrials.com/pain/NCT00558870/
Component and Couple Analysis of Cancer Communications
Component and Couple Analysis of Cancer Communication CHESS, the Comprehensive Health Enhancement Support System is an innovative technology that provides information, social support and skills training to women with breast cancer. Previous CHESS clinical trials found improved patient outcomes but little is known about what services in CHESS produce those results. This study will examine whether breast cancer patient outcomes change when conceptually distinct CHESS services (information, social support, and skills training) are systematically added to a patients treatment resources. Primary Aims: - Determine the relative efficacies of different types of cancer communication treatments when they are presented alone or in combination - Determine routes or processes via which these elements work - Determine for whom the different treatment types work best.
NCT00468741 — Breast Cancer
Status: Completed
http://inclinicaltrials.com/breast-cancer/NCT00468741/